Bellicum Pharmaceuticals
A clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.
Launch date
Employees
Market cap
AUD1.2m
Enterprise valuation
(AUD70m) (Public information from Feb 2024)
Share price
$0.0747 BLCM
Houston Texas (HQ)
Authorizing premium user...